A major advance in tumor biotherapy is the successful application of molecularly targeted therapeutic agents, which are mainly of two classes, monoclonal antibodies and small molecule compounds. Monoclonal antibodies and small molecule compounds are commonly used: Herceptin (Herceptin), Rituximab (Meroval), IMC-C225 (Erbitux) and Avastin, etc. Small molecule compounds are commonly used: Glivec (STI571, Gleevec), ZD1839 (Iressa), OSI774 (Tarceva ). Overexpression or over-activation of tyrosine kinase receptors is seen in many tumors, and this over-activation often leads to activation of downstream signaling pathways, ultimately leading to cell transformation, proliferation and resistance to apoptosis, which are closely associated with tumor development. Therefore, blocking the tyrosine kinase receptor signaling pathway will stop the excessive cell proliferation. The successful introduction of the above three EGFR tyrosine kinase inhibitors has fully demonstrated their feasibility. The implementation of molecular targeted therapy requires firstly the correct search of molecular targets by immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH) techniques, and according to their results, suitable targeted drugs are screened, which can be treated by simple biological therapy, biochemotherapy, bioradiotherapy and other methods. The efficacy is evaluated by PET/CT, CT, MRI, tumor markers and other examination methods after completing a certain course of treatment time and medication, and attention is paid to dose reduction and maintenance during the treatment process and close follow-up.